Treatment with TT-OVA-PeptiCRAd—an oncolytic adenovirus coated with MHC I-restricted tumor-specific peptides and tetanus toxoid (TT) pathogen-specific MHC II-restricted peptides—significantly enhanced antitumor efficacy and induced TT-specific, CD40 ligand-expressing CD4+ T helper cells and maturation of antigen-presenting cells. Here, CD4 is linked to neoplasm.